logo-loader

Humanigen chosen by National Institute of Health's upcoming coronavirus clinical trial

Published: 10:40 31 Jul 2020 EDT

Humanigen Inc (OTCQB:HGEN) CEO Cameron Durrant tells Proactive that its lead drug candidate lenzilumab was selected for use in the National Institute of Health’s upcoming coronavirus trial.

Durrant says lenz will be evaluated in the National Institute of Allergy and Infectious Diseases’ (NIAID) Big Effect Trial (BET) in patients hospitalized with COVID-19.

Poseidon Nickel signs binding agreement with Mineral Resources to divest...

Departing Poseidon Nickel Ltd (ASX:POS, OTC:PSDNF) CEO Craig Jones and incoming CEO Brendan Shalders join Proactive’s Jonathan Jackson to discuss the divestment of Lake Johnston to Mineral Resources Ltd (ASX:MIN). Jones, who has played a pivotal role in this strategic move, shared insights on...

4 hours, 24 minutes ago